Search - tctmd.com

Displaying 141 - 160 of 234

Sort: Relevancy | Date

HF Triple Therapy Doesn’t Seem Effective in True Preserved HF

Shelley Wood

May 25, 2022

News Conference News ESC Heart Failure 2022

Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients

Shelley Wood

May 23, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Daily News

The Hunt for Protein Culprits in COVID-19’s Cardiac Complications

Michael O'Riordan

May 06, 2022

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

News Daily News

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

Caitlin E. Cox

May 03, 2022

News Conference News HRS 2022

Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era

Todd Neale

May 02, 2022

News Daily News

Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries

Todd Neale

April 20, 2022

News Daily News

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

Caitlin E. Cox

April 15, 2022

News Conference News ACC 2022

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

L.A. McKeown

April 08, 2022

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

News Daily News

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

L.A. McKeown

March 22, 2022

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

L.A. McKeown

March 11, 2022

News Conference News STS 2022

Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression

Michael O'Riordan

February 04, 2022

News Opinion CV Team Dispatch

December 2021 News Roundup

L.A. McKeown

December 01, 2021

News Conference News AHA 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Michael O'Riordan

November 19, 2021

News Conference News AHA 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

Todd Neale

November 17, 2021

News Conference News TCT 2021

GUIDE-HF Hints That Hemodynamic-Guided Management Works in HFpEF

Michael O'Riordan

November 06, 2021

News Opinion CV Team Dispatch

November 2021 News Roundup

L.A. McKeown

November 01, 2021

News Features

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

Shelley Wood

October 08, 2021

Advertisement

HF Triple Therapy Doesn’t Seem Effective in True Preserved HF

Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients

Dapagliflozin Boosts Health Status Across LVEF Range

The Hunt for Protein Culprits in COVID-19’s Cardiac Complications

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era

Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

Guideline-Directed Therapies Underused in Frail HF Patients

Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression

December 2021 News Roundup

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

GUIDE-HF Hints That Hemodynamic-Guided Management Works in HFpEF

November 2021 News Roundup

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content